Yi Li

TL;DR: MSCs delivered to ischemic brain tissue through an intravenous route provide therapeutic benefit after stroke and may provide a powerful autoplastic therapy for stroke.

TL;DR: Intravenously administered HUCBC enter brain, survive, migrate, and improve functional recovery after stroke in rats, and may provide a cell source to treat stroke.

TL;DR: Neurologic benefit resulting from hMSC treatment of stroke in rats may derive from the increase of growth factors in the ischemic tissue, the reduction of apoptosis in the penumbral zone of the lesion, and the proliferation of endogenous cells in the subventricular zone.

TL;DR: It is suggested that intravenous administration of cell-free MSC-generated exosomes post stroke improves functional recovery and enhances neurite remodeling, neurogenesis, and angiogenesis and represents a novel treatment for stroke.

TL;DR: It is found that MSC treatment of rats subjected to middle cerebral artery occlusion significantly increased microRNA 133b (miR‐133b) level in the ipsilateral hemisphere and this study provides the first demonstration that M SCs communicate with brain parenchymal cells and may regulate neurite outgrowth by transfer of miR‐ 133b to neural cells via exosomes.